Novamab Announces Completion of Nearly RMB 300 Million Series B+ Financing to Advance Inhaled and Oral Nanobody Pipeline

Recently, Shanghai Novamab Biopharmaceuticals Co., Ltd. ("Novamab"), a biotechnology company focusing on the research and development of innovative nanobody drugs, officially announced the successful completion of its Series B+ financing round, raising nearly 300 million RMB. This round of financing was led by existing shareholder Qiming Venture Partners, with participation from existing shareholders Jiuyu Investment, Fuho Capital, and new shareholders including Guangxi Nanwan Baiao Phase I Venture Capital Partnership (Limited Partnership), Kinghall Ventures, Beijing Zhaode Investment Co., Ltd., Shangli Investment, and Zhongshan Yueke.

The funds raised in this round will be mainly used in three directions: First, to advance the Phase IIb clinical study of the company’s core inhalation nanobody pipeline LQ036, for which patient enrollment is currently proceeding smoothly; second, to focus on promoting the development and implementation of the oral nanobody platform and related pipelines, further refining the technological platform layout; third, to strengthen team building by adding key R&D and operational talents to support the company's sustainable development.

Novamab Focuses on the R&D Field of Nanobody Innovative Drugs. After Years of Development, It Has Established a Complete R&D, CMC, and Pilot Production System, and Built a Mature Nanobody Innovation Technology Platform. It Is One of the Companies in China with Full-process Development Capabilities for Inhalable Nanobodies. The Company Deeply Cultivates the Nanobody Sector, Focusing on Unmet Clinical Needs, and Develops Biologic Innovative Drugs with Independent Intellectual Property Rights Based on Its Own Technology Platform.